Conference Presentation: Entrada Therapeutics CEO Dipal Doshi will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, which is expected to attract investor attention and enhance the company's visibility.
Live Webcast: The presentation will be available via live webcast on Entrada's Investor Relations website, with a replay accessible for 30 days post-event, aimed at increasing engagement and transparency with potential investors.
Company Overview: Entrada Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuromuscular and ocular diseases, showcasing its cutting-edge position in the biopharmaceutical sector.
Product Development: The company is advancing a robust portfolio of RNA and protein-based programs, particularly targeting treatments for Duchenne muscular dystrophy, indicating its potential in addressing challenging diseases.
TRDA
$11.37+Infinity%1D
Analyst Views on TRDA
Wall Street analysts forecast TRDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TRDA is 16.50 USD with a low forecast of 13.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast TRDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TRDA is 16.50 USD with a low forecast of 13.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 11.030
Low
13.00
Averages
16.50
High
20.00
Current: 11.030
Low
13.00
Averages
16.50
High
20.00
Roth Capital
Buy
downgrade
$17 -> $13
2025-11-06
Reason
Roth Capital
Price Target
$17 -> $13
2025-11-06
downgrade
Buy
Reason
Roth Capital lowered the firm's price target on Entrada Therapeutics to $13 from $17 and keeps a Buy rating on the shares. Management guided that preliminary proof-of-concept efficacy results from the ongoing global Phase 1/2 study of ENTR-601-44 and ENTR-601-45 are expected in 2Q26 and mid-2026, respectively, the analyst tells investors in a research note. While the firm remains enthusiastic about the company's pipeline programs, it lowered its price target on the shares to reflect the broader market sentiment and advances made by competing agents.
Goldman Sachs
Paul Choi
initiated
2025-09-17
Reason
Goldman Sachs
Paul Choi
Price Target
2025-09-17
initiated
Reason
Goldman Sachs analyst Paul Choi initiated coverage of Entrada Therapeutics with an Early-Stage Biotech designation, saying the company's Endosomal Escape Vehicle platform is differentiated from other delivery peptide approaches. It sees "best-in-class potential."
Roth Capital
Buy
downgrade
$21 -> $17
2025-08-07
Reason
Roth Capital
Price Target
$21 -> $17
2025-08-07
downgrade
Buy
Reason
Roth Capital lowered the firm's price target on Entrada Therapeutics to $17 from $21 and keeps a Buy rating on the shares after meeting with its management to discuss the company's DMD clinical programs, particularly, ENTR-601-44 and ENTR-601-45. The company's robust cash position and multiple clinical data readouts anticipated in 2026 drive the firm's optimism, though Roth is also acknowledging the broader negative sentiment enshrouding the company's stock, partly fueled by a lack of value driving data catalyst events in 2025, the analyst tells investors in a research note.
Roth Capital
Boobalan Pachaiyappan
Buy
downgrade
$23 -> $21
2025-05-12
Reason
Roth Capital
Boobalan Pachaiyappan
Price Target
$23 -> $21
2025-05-12
downgrade
Buy
Reason
About TRDA
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The Company is advancing a robust development portfolio of RNA-, antibody- and enzyme-based programs for the potential treatment of neuromuscular, ocular, metabolic and immunological diseases, among others. It is engaged in preclinical lead optimization efforts in both neuromuscular and non-neuromuscular disease and discovery efforts to advance platform applications. Its lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne who are exon 44, 45, 50 and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
